Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Surface Membrane Barriers01:18

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TENTACLES: a consensus machine learning tool for robust biomarker discovery in heterogeneous data.

BioData mining·2026
Same author

Establishment and application of a vesicle extraction method for clinical strains of <i>Pseudomonas aeruginosa</i>.

Microbiology spectrum·2026
Same author

<i>In vitro</i> cellular tropism and immunomodulatory response to rVSVΔG-ZEBOV-GP in human cells derived from tissues associated with adverse events.

Microbiology spectrum·2026
Same author

Correction: Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Frontiers in immunology·2026
Same author

Long non-coding RNAs in response to Ebola virus vaccine-induced immunity.

Frontiers in immunology·2026
Same author

Immunogenicity evaluation of altSonflex1-2-3 <i>Shigella</i> vaccine across mice, rats, and rabbits to inform human translational insights.

Frontiers in immunology·2026
Same journal

Human Papillomavirus (HPV)-The Interplay between Vaginal Microbiota and HPV, along with its Prevention.

Current HIV research·2026
Same journal

Metabolic Syndrome Prevalence Among People Living With HIV: A Single-Center Study From Türkiye.

Current HIV research·2026
Same journal

Weight Change with Long-Acting Cabotegravir Plus Rilpivirine in People with HIV: Targeted Review and Meta-Analysis.

Current HIV research·2026
Same journal

Corrigendum to: Impact of HIV-1 Tat on FDFT1 Suppression, Changes in Cholesterol Level, and KSHV Replication in BCBL1 Cells.

Current HIV research·2026
Same journal

Study of Class I HDAC-1, -2, and -3 Inhibitors Designed by Bioisosteric Replacement of Zinc Binding Groups and Caps of Traditional Pan Inhibitors: An <i>In Silico</i> Approach.

Current HIV research·2026
Same journal

Sociodemographic and Clinical Characteristics of Individuals Receiving Post-Exposure Prophylaxis (PEP) for HIV in the Republic of Cyprus: A Cross-sectional Study.

Current HIV research·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Mucosal adjuvants.

Ali M Harandi1, Donata Medaglini

  • 1Department of Microbiology & Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Sweden. ali.harandi@microbio.gu.se

Current HIV Research
|April 1, 2010
PubMed
Summary
This summary is machine-generated.

Developing mucosal vaccines is crucial for combating infections. Safe and effective mucosal adjuvants and delivery systems are needed for human use, with several promising agents currently under investigation.

More Related Videos

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA&#45;Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization
10:06

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Published on: September 2, 2022

Related Experiment Videos

Last Updated: Jun 14, 2026

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA&#45;Specific Systemic and Mucosal Responses
06:02

Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses

Published on: February 23, 2024

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization
10:06

Cellular Affinity of Particle-Stabilized Emulsion to Boost Antigen Internalization

Published on: September 2, 2022

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Mucosal tissues are primary sites for pathogen entry and infection.
  • Developing vaccines against mucosal pathogens is a high priority.
  • Few mucosal vaccines are currently approved for human use.

Purpose of the Study:

  • To provide an overview of mucosal immunization strategies.
  • To review mucosal adjuvants and delivery systems for vaccine development.
  • To focus on mucosal adjuvants nearing clinical application.

Main Methods:

  • Review of existing literature on mucosal immunization.
  • Analysis of immunomodulatory agents and delivery systems.
  • Emphasis on adjuvants with potential for human clinical trials.

Main Results:

  • Mucosal immunization generates protective immunity but faces challenges.
  • Various immunomodulatory agents (toxin-based, TLR mimetics, non-TLR) show promise in animals.
  • Delivery systems are also being explored for mucosal administration.

Conclusions:

  • Development of safe and effective mucosal adjuvants and delivery systems is essential for advancing mucosal vaccines.
  • Further research is needed to establish the human clinical utility of promising mucosal adjuvants.
  • Bridging the gap between animal studies and human application is critical for future mucosal vaccine success.